145,282 members

Skip to content. | Skip to navigation

News

Skin cancer drug not cost effective for routine NHS use

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Skin cancer drug not cost effective for routine NHS use

NICE has started a consultation on draft guidance which does not recommend the routine use of nivolumab (Opdivo; Bristol-Myers Squibb) as an option after surgery for some people with melanoma.

For the last 2 years nivolumab was recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. More….